



# NICE and liothyronine

## How does the NICE Thyroid Guideline Link to RMOG Liothyronine Prescribing Guidance?

The NICE Guideline on thyroid disease assessment and management supports the RMOG prescribing guidance for liothyronine.

This document outlines how to find the links in the NICE guideline to the RMOG guidance, for anyone who may be told that NICE does not support liothyronine prescribing, or that liothyronine is not available on the NHS- both of which are incorrect.

### 1/ To find the link in the pdf of the guideline:

- <https://www.nice.org.uk/guidance/ng145>
- **Download the guideline as a PDF**
- Page 33 Managing primary hypothyroidism
- Recommendations 1.3.3 to 1.3.7
- Page 34 'Why the committee made these recommendations'
- At end of first paragraph, superscript [5] links to footnote at end of Page 50, and to  
['NHS England's specialist pharmacy service has produced advice on prescribing liothyronine' \(RMOG guidance\)](#)

### 2/ To find the link when reading the guideline online:

**NB:** When reading the guideline online, the link is in the NICE Rationale and Impact section, which is reached as follows:

**The Thyroid Trust**

[www.thyroidtrust.org](http://www.thyroidtrust.org)

Registered charity number 1183292

**Registered office:** 15 Great College Street, London, SW1P 3RX

- <https://www.nice.org.uk/guidance/ng145/chapter/Rationale-and-impact>
- Section: Managing primary hypothyroidism
- Recommendations 1.3.3 to 1.3.7
- Why the committee made the recommendations
- Thyroid hormone replacement
- At the end of first paragraph footnote [5] leads to link 'NHS England's specialist pharmacy service has produced [advice on prescribing liothyronine](#) (RMOC Guidance)

### **NICE response to stakeholder comments**

In response to stakeholders' comments to the draft NICE guideline, including NHS England and The Thyroid Trust, that the July 2019 RMOC detailed Prescribing Guidance was not included in the NICE draft guideline where NICE says '*Do not routinely offer liothyronine for primary hypothyroidism*', the response from NICE to each comment was: '*A footnote has been added to the rationale and impact section for the recommendation 1.3.4 on liothyronine cross referring to the latest Regional Medicines Optimisation Committee (RMOC) guidance issued to Clinical Commissioning Groups (CCGs) on the prescribing of liothyronine*' (<https://www.sps.nhs.uk/wp-content/uploads/2019/07/RMOC-Liothyronine-guidance-V2.6-final-1.pdf>)

**The Thyroid Trust**

[www.thyroidtrust.org](http://www.thyroidtrust.org)

Registered charity number 1183292

**Registered office:** 15 Great College Street, London, SW1P 3RX